| Literature DB >> 34555877 |
L Pedone Anchora, N Bizzarri, V Gallotta, V Chiantera, F Fanfani, A Fagotti, F Cosentino, G Vizzielli, V Carbone, G Ferrandina, G Scambia.
Abstract
Background: Recently, it has been sustained that only surgeons skilled in minimally invasive radical hysterectomy (MI-RH) could provide valuable oncological outcomes in early-stage cervical cancer. Still, literature lacks data correlating surgeon experience with patient survival rate. We aimed to investigate the impact of surgeon training on this rate.Entities:
Year: 2021 PMID: 34555877 PMCID: PMC8823276 DOI: 10.52054/FVVO.13.3.035
Source DB: PubMed Journal: Facts Views Vis Obgyn ISSN: 2032-0418
Figure 1Comprehensive gynaecological oncology surgeon (GOS) learning curve —Trend of the learning curve was calculated considering the cumulative sum of progressive improvement on patients’ survival according to the increase of number performed by a GOS during his/her career.
Figure 2Disease-free survival curve according to gynaecological oncology surgeon (GOS) experience.
Surgical and clinical-pathological characteristics of the series.
| Characteristics | N. (%) |
|---|---|
| Patients | 243 |
| Median Age, yrs (range) | 47 (25-80) |
| Radicality of Surgerya | |
| - Type A | 43 (17.7) |
| - Type B | 111 (45.7) |
| - Type C | 89 (36.6) |
| Lymph Node Surgery | |
| - Sentinel Lymph Node Biopsy | 47 (19.3) |
| - Pelvic Lymphadenectomy | 196 (80.7) |
| Aortic Lymphadenectomy | |
| - No | 159 (65.4) |
| - Yes | 84 (34.6) |
| Pathological FIGO stage | |
| - IA1 | 52 (21.4) |
| - IA2 | 15 (6.2) |
| - IB1 | 131 (53.9) |
| - IB2 | 8 (3.3) |
| - IIA1 | 9 (3.7) |
| - IIA2 | 5 (2.1) |
| - IIB | 23 (9.5) |
| Histology | |
| - Squamous carcinoma | 157 (64.6) |
| - Other | 86 (35.4) |
| Grading | |
| - G1 / G2 | 178 (73.3) |
| - G3 | 53 (21.8) |
| Tumor diameter | |
| - ≤ 20 mm | 157 (64.6) |
| - > 20 mm | 86 (35.4) |
| Lymphovascular space invasion | |
| - Absent | 154 (63.4) |
| - Present | 89 (36.6) |
| Lymph node status | |
| - Negative | 198 (81.5) |
| - Positive | 45 (18.5) |
| Adjuvant therapy | |
| - No | 140 (57.6) |
| - Radiotherapy | 46 (18.9) |
| - Chemotherapy | 4 (1.6) |
| - concomitant chemoradiotherapy | 53 (21.8) |
aaccording to Querleu and Morrow classifications
Cox regression analyses association between gynaecological oncology surgeon (GOS) experience, defined by sequential dichotomizations of the number of MI-RS performed by the GOS, and disease-free survival.
| Number of MI-RH performed | Hazard Ratio | 95% CI* | p value |
|---|---|---|---|
| ≤ 1 vs ≥ 2 | 0.891 | 0.215-3.373 | 0.880 |
| ≤ 2 vs ≥ 3 | 1.968 | 0.472-8.202 | 0.353 |
| ≤ 3 vs ≥ 4 | 1.439 | 0.508-4.078 | 0.494 |
| ≤ 4 vs ≥ 5 | 0.974 | 0.425-2.231 | 0.950 |
| ≤ 5 vs ≥ 6 | 0.705 | 0.338-1.468 | 0.350 |
| ≤ 6 vs ≥ 7 | 0.665 | 0.331-1.337 | 0.252 |
| ≤ 7 vs ≥ 8 | 0.615 | 0.312-1.211 | 0.160 |
| ≤ 8 vs ≥ 9 | 0.632 | 0.323-1.236 | 0.180 |
| ≤ 9 vs ≥ 10 | 0.558 | 0.287-1.085 | 0.086 |
| ≤ 10 vs ≥ 11 | 0.581 | 0.299-1.130 | 0.110 |
| ≤ 11 vs ≥ 12 | 0.518 | 0.265-1.012 | 0.054 |
| ≤ 12 vs ≥ 13 | 0.511 | 0.260-1.007 | 0.052 |
| ≤ 13 vs ≥ 14 | 0.499 | 0.251-0.992 |
|
| ≤ 14 vs ≥ 15 | 0.568 | 0.286-1.131 | 0.107 |
| ≤ 15 vs ≥ 16 | 0.460 | 0.225-0.941 |
|
| ≤ 16 vs ≥ 17 | 0.372 | 0.174-0.796 |
|
| ≤ 17 vs ≥ 18 | 0.343 | 0.156-0.756 |
|
| ≤ 18 vs ≥ 19 | 0.321 | 0.140-0.737 |
|
| ≤ 19 vs ≥ 20 | 0.351 | 0.153-0.805 |
|
| ≤ 20 vs ≥ 21 | 0.389 | 0.169-0.893 |
|
| ≤ 21 vs ≥ 22 | 0.424 | 0.185-0.974 |
|
| ≤ 22 vs ≥ 23 | 0.471 | 0.205-1.083 | 0.076 |
| ≤ 23 vs ≥ 24 | 0.526 | 0.229-1.210 | 0.131 |
| ≤ 24 vs ≥ 25 | 0.466 | 0.193-1.128 | 0.090 |
| ≤ 26 vs ≥ 27 | 0.508 | 0.210-1.231 | 0.134 |
| ≤ 26 vs ≥ 27 | 0.567 | 0.234-1.375 | 0.210 |
| ≤ 27 vs ≥ 28 | 0.634 | 0.262-1.538 | 0.314 |
| ≤ 28 vs ≥ 29 | 0.697 | 0.287-1691 | 0.425 |
| ≤ 29 vs ≥ 30 | 0.528 | 0.310-1.823 | 0.528 |
| ≤ 30 vs ≥ 31 | 0.481 | 0.169-1.368 | 0.170 |
| ≤ 31 vs ≥ 32 | 0.502 | 0.176-1.1430 | 0.197 |
| ≤ 32 vs ≥ 33 | 0.524 | 0.184-1.495 | 0.227 |
| ≤ 33 vs ≥ 34 | 0.547 | 0.192-1.562 | 0.260 |
| ≤ 34 vs ≥ 35 | 0.573 | 0.201-1.639 | 0.299 |
| ≤ 35 vs ≥ 36 | 0.602 | 0.210-1.723 | 0.334 |
| ≤ 36 vs ≥ 37 | 0.633 | 0.221-1.814 | 0.633 |
| ≤ 37 vs ≥ 38 | 0.468 | 0.142-1.542 | 0.212 |
| ≤ 38 vs ≥ 39 | 0.479 | 0.145-1.581 | 0.227 |
| ≤ 39 vs ≥ 40 | 0.503 | 0.152-1.659 | 0.259 |
Bold values indicate statistically significant; *CI: confidence interval
Clinical-pathological characteristics of patients grouped according to gynaecological oncology surgeon (GOS) experience at the time of their surgery.
| GOS during the first part of the learning path (< 18 MI-RH) | GOS during the second part of the learning path (> 19 MI-RH) | ||
|---|---|---|---|
| Characteristics | N. (%) | N. (%) | p Value |
| Patients | 128 | 115 | 243 |
| Pathological FIGO stage | |||
| - IA1 | 31 (24.2) | 21 (18.3) | |
| - IA2 | 11 (8.6) | 4 (3.5) | |
| - IB1 | 65 (50.8) | 66 (57.4) | |
| - IB2 | 2 (1.6) | 6 (5.2) | |
| - IIA1 | 3 (2.3) | 6 (5.2) | |
| - IIA2 | 4 (3.1) | 1 (0.9) | |
| - IIB | 12 (9.4) | 11 (9.6) | 0.154 |
| Histology | |||
| - Squamous carcinoma | 86 (67.2) | 71 (61.7) | |
| - Other | 42 (32.8) | 44 (38.3) | 0.375 |
| Grading | |||
| - G1 / G2 | 97 (75.8) | 90 (78.3) | |
| - G3 | 31 (24.2) | 25 (21.7) | 0.678 |
| Tumor diameter | |||
| - ≤ 20 mm | 86 (67.2) | 73 (63.5) | |
| - > 20 mm | 42 (32.8) | 42 (36.5) | 0.540 |
| Lymphovascular space invasion | |||
| - Absent | 79 (61.7) | 75 (65.2) | |
| - Present | 49 (38.3) | 40 (34.8) | 0.850 |
| Lymph node status | |||
| - Negative | 102 (79.7) | 96 (83.5) | |
| - Positive | 26 (20.3) | 19 (16.5) | 0.448 |
| Adjuvant therapy | |||
| - No | 77 (60.2) | 66 (57.4) | |
| - Radiotherapy | 28 (21.9) | 15 (13.0) | |
| - Chemotherapy | 2 (1.6) | 2 (1.7) | |
| - concomitant chemoradiotherapy | 21 (16.4) | 32 (27.8) | 0.171 |
Cox’s regression uni- and multi-variate analyses of pathologic and surgical parameters associated to disease-free survival.
| Univariate Analysis | Multivariate Analysis | |||
|---|---|---|---|---|
| Characteristics | HR (95% CI) * | p Value | ß | p Value |
| Pathological FIGO stage | 1.444 (1.004 – 2.078) |
| / | 0.651 |
| Histology | 1.075 (0.534 – 2.162) | 0.840 | / | / |
| Grading | 1.402 (0.687 – 2.863) | 0.354 | / | / |
| Tumor diameter | 4.164 (2.055 – 8.438) |
| 1.356 |
|
| Lymphovascular space invasion | 1.560 (1.199 – 2.030) |
| / | 0.120 |
| Lymph nodal status | 1.267 (1.003 – 2.268) |
| / | 0.202 |
| GOS experience (< 18 vs > 19 MI-RH) | 0.321 (0.140 – 0.737) |
| -1.013 |
|
* HR: Hazzard Ratio, CI: confidence interval; Bold values indicate statistically significant